Elon Musk’s response to a Wall Street Journal article alleging his use of hard illicit drugs drew attention, with concerns raised about his well-being and the impact on his companies’ government contracts.
Meanwhile, Mind Medicine Inc. (NASDAQ:MNMD) aims to transform the perception of psychedelics, focusing on their potential for treating serious mental health issues.
The company’s research suggests that psychedelic-inspired medicines could address underlying causes of distress in the brain, aiming to treat conditions such as anxiety, autism, opiate withdrawal, depression, and cluster headaches.
While traditional pharmaceuticals have faced health concerns, MindMed seeks to offer an alternative approach.
Although the company’s stock has fluctuated, it continues its research with the hope of providing solutions without relying on traditional big pharma.
There are startups in the mental wellness space, such as Choose Your Horizon, offering at-home psychedelic therapy for various conditions through telemedicine and utilizing equity crowdfunding for investment.
Read Also:
Rep. Ilhan Omar Accused Of Committing Treason, Faces Censure Resolution
Man Who Leaked Trump’s Tax Returns Learns His Fate
